, Volume 51, Issue 3, pp 323-330

Prostaglandin-endoperoxide synthase genesCOX1 andCOX2 — novel modifiers of disease severity in cystic fibrosis patients

Purchase on Springer.com

$39.95 / €34.95 / £29.95*

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Cystic fibrosis (CF) is one of the most common autosomal recessive diseases among Caucasians caused by a mutation in theCFTR gene. However, the clinical outcome of CF pulmonary disease varies remarkably even in patients with the sameCFTR genotype. This has led to a search for genetic modifiers located outside theCFTR gene. The aim of this study was to evaluate the effect of functional variants in prostaglandin-endoperoxide synthase genes (COX1 andCOX2) on the severity of lung disease in CF patients. To the best of our knowledge, it is the first time when analysis ofCOX1 andCOX2 as potential CF modifiers is provided. The study included 94 CF patients homozygous for F508del mutation ofCFTR. To compare their clinical condition, several parameters were recorded, e.g. a unique clinical score: disease severity status (DSS). To analyse the effect of non-CFTR genetic polymorphisms on the clinical course of CF patients, the whole coding region ofCOX1 and selectedCOX2 polymorphisms were analysed. Statistical analysis of genotype-phenotype associations revealed a relationship between the heterozygosity status of identified polymorphisms and better lung function. These results mainly concernCOX2 polymorphisms: −765G>C and 8473T>C. TheCOX1 andCOX2 polymorphisms reducing COX protein levels had a positive effect on all analysed clinical parameters. This suggests an important role of these genes as protective modifiers of pulmonary disease in CF patients, due to inhibition of arachidonic acid conversion into prostaglandins, which probably reduces the inflammatory process.